What Is a “Good” Client?
This question came up recently when I was describing one of our current clients as a "good" client. But what exactly is a "good" client? Three things come to…
Menu
Temporary Down: Lessons Learned Before #BIO2015
OK, so the new One-on-One Partnering system has not had a stellar introduction. We're not here to complain about it, as this has been well covered on LinkedIn and…
Why Does It Take So Darn Long?
What follows is a true story. In 2013, we were engaged to out-license a series of Preclinical assets. One of these assets was in a therapeutic area which had very few…
Adaptive Licensing: An Idea Ready For Prime Time?
We just finished reading a terrific academic piece by Jack Scannell and colleagues at the University of Oxford. Entitled Financial Returns on R&D: Looking Back at History, Looking Forward…
What Pharma Want: Comments On Article
Earlier this month, our friends at Biotech and Money published a transcript from a panel discussion at their London 2015 congress. The discussion was quite interesting, and we encourage…
Preparing for #BIO2015 in Philadelphia…Already?
We've started preparing for the BIO convention in Philadelphia in June. Preparing? Already? Yes. Why start now? We'll give you three reasons: New Partnering Interface - BIO has unveiled a…
Independent Consultants Wanted
Are you an independent consultant? Are you looking for a new platform or channel to help grow and expand your practice? Why not join us! Lacerta Bio is looking…
Employee-Free Biotechs: A Virtual Panacea?
Last week Reuters published an article summarizing the "virtual" biotech business model. It was a strange article, considering that this is not a new approach. Indeed, we wrote about this…
Made in China: Chidamide
Today, Derek Lowe points out that Shenzhen Chipscreen received CFDA approval for chid amide (Epidaza), the first drug to be completely discovered, developed and approved exclusively in China.…
On Failure
These past few weeks I have noticed how negative and bimodal we have become when clinical results are announced. More and more, Phase II and III results are labeled #FAIL…
- Go to the previous page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- …
- 33
- Go to the next page